A vaccine project funded by the Federal Ministry for Economic Affairs and Energy develops a second generation COVID-19 vaccine

A vaccine project funded by the EXIST programme initiated by the Federal Ministry for Economic Affairs and Energy (Germany) is developing a second generation Covid-19 vaccine. The "Prime Vector Technologies - PVT" start-up from Tübingen is engaged in a successful demonstration of Germany's scientific capabilities. This new generation of vaccines directly addresses the most common SARS-CoV-2 variants. In addition to stimulating the strongest and broadest possible antibody-based immune response to the SARS-CoV-2 virus, it creates specific T-cells. This also increases the protection against potential virus mutations. Another goal stated for the new vaccine generation is to provide a suitable booster immunisation when the antibody response drops in COVID-19 patients or immunised people.

Federal Minister Altmaier is delighted by the latest stage of the development of the SARS-CoV-2 vaccine and explains: "Germany and its Prime Vector Technologies vaccine project funded by EXIST is at the forefront of development of second-generation vaccines. We are very pleased with this, because research and innovation are crucial in the fight against COVD-19".

With a further increase of €18 million, the Federal Ministry for Economic Affairs and Energy is supporting the start-up project as it tests the vaccine candidate in humans in the first two clinical phases. The licensing process for the PVT vaccine candidate could start at the end of 2021.

Professor Dr Peter Kremsner, a renowned expert and head of an EU vaccine study at Tübingen University Hospital welcomed the polyvalent COVID-19 vaccine, saying: "The introduction by the EXIST spin-off PVT of this vaccine candidate strengthens the position of Tübingen University Hospital as one of the world centres for COVID-19 vaccine development." The new vaccine is also at the centre of international attention. A South East Asian pharmaceutical company, for instance, would be very interested in acquiring a licence for it and starting large-scale vaccine production in 2021. To supply the German population, the Federal Ministry for Economic Affairs and Energy has already secured a licence-free provision of PVT vaccine doses.

For the last 20 years, the Federal Ministry for Economic Affairs and Energy has been successfully using the "EXIST - Business start-ups in science" programme to fund start-up spin-offs from German universities and science.

For further information, please visit:
https://www.prime-vector-technologies.com

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...